Back to news

Zealand Pharma announces initiation of the Phase 2 ZYNERGY trial of petrelintide co-administered with enicepatide in people with obesity or overweight

Globe Newswire•18/11/2026•01:00 ET
0

Key Highlights

  • ➤Zealand Pharma (ZEAL) initiated Phase 2 ZYNERGY trial of petrelintide and enicepatide.
  • ➤ZYNERGY will evaluate three combination dosing regimens over 40 weeks.
  • ➤Trial targets 480 participants with obesity or overweight and weight-related comorbidity.
  • ➤Roche sponsors and conducts ZYNERGY, designed to support Phase 3 dose selection.
  • ➤Primary endpoint is percentage change in body weight at week 40.

Expert Statements

David Kendall, Chief Medical Officer at Zealand Pharma

“The initiation of the Phase 2 trial with petrelintide co-administered with enicepatide marks an important milestone in our ambition to build a leading amylin-based franchise for chronic weight management”

David Kendall, Chief Medical Officer at Zealand Pharma

“As demonstrated in separate Phase 2 trials, petrelintide’s tolerability profile, which is largely comparable to placebo, paired with the promising efficacy of enicepatide, makes this combination study a compelling and natural next step.”

David Kendall, Chief Medical Officer at Zealand Pharma

“This study is designed to explore the effect of two complementary mechanisms, aiming to deliver both substantial weight loss and an improvement in cardiometabolic risk markers while maintaining a competitive tolerability profile.”

Zealand Pharma announces initiation of the Phase 2 ZYNERGY trial of petrelintide co-administered with enicepatide in people with obesity or overweight * The Phase 2 ZYNERGY trial investigates the efficacy and safety of petrelintide co-administered with enicepatide in people with obesity or overweight with at least one weight-related comorbidity * The ZYNERGY trial evaluates three dosing regimens of the combination of petrelintide and enicepatide over 40 weeks of treatment * The combination is designed to combine the effects of an amylin analog and a GLP-1/GIP receptor agonist to deliver compelling weight loss and potentially improvement in cardiometabolic risk markers while maintaining a competitive tolerability profile Copenhagen, Denmark, November 18, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming metabolic health so millions can live without limits, today announces initiation of ZYNERGY, a Phase 2 dose-finding trial in participants with obesity or overweight with at least one weight-related comorbidity. The trial compares once-weekly co-administration of petrelintide (an investigational human amylin analog), and enicepatide (an investigational GLP-1/GIP receptor agonist), versus placebo, petrelintide monotherapy, and enicepatide monotherapy with regards to effect on body weight, safety, and tolerability(1).

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in